FGEN.O
Latest Trade
13.27USDChange
-0.37(-2.71%)Volume
1,725,559Today's Range
-
13.7352 Week Range
-
57.21As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 13.64 |
|---|---|
Open | 13.65 |
Volume | 1,725,559 |
3M AVG Volume | 26.40 |
Today's High | 13.73 |
Today's Low | 13.11 |
52 Week High | 57.21 |
52 Week Low | 13.11 |
Shares Out (MIL) | 92.13 |
Market Cap (MIL) | 1,222.54 |
Forward P/E | -9.23 |
Dividend (Yield %) | -- |
Fibrogen And HiFiBiO Announce Partnership To Advance Therapies For Cancer And Autoimmune Disease
FibroGen Reports Q1 Loss Per Share $0.78
Fibrogen Receives Fast Track Designation From The U.S. FDA For Pamrevlumab For The Treatment Of Duchenne Muscular Dystrophy
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).
Industry
Business Services
Contact Info
409 Illinois St
SAN FRANCISCO, CA
94158-2509
United States
+1.415.9781200
http://www.fibrogen.comExecutive Leadership
James A. Schoeneck
Chairman of the Board
Enrique A. Conterno
Chief Executive Officer, Director
Pat Cotroneo
Chief Financial Officer
Christine L. Chung
Senior Vice President, China Operations
Elias Kouchakji
Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 6.42 |
Price To Book (MRQ) | 3.29 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 14.19 |
LT Debt To Equity (MRQ) | 10.82 |
Return on Investment (TTM) | -27.23 |
Return on Equity (TTM) | -22.64 |
* FIBROGEN - ON JULY 8, UNITS AND ASTRAZENECA ENTERED INTO AN AMENDMENT TO AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
* FIBROGEN ANNOUNCES FIRST PATIENT ENROLLED IN PAMREVLUMAB CLINICAL TRIAL IN PATIENTS HOSPITALIZED IN U.S. WITH ACUTE COVID-19
* FIBROGEN ANNOUNCES NEW ROXADUSTAT DATA PRESENTED AT 2020 ERA-EDTA VIRTUAL CONGRESS
* FIBROGEN ANNOUNCES FIRST PATIENT ENROLLED IN PAMREVLUMAB CLINICAL TRIAL IN PATIENTS HOSPITALIZED IN ITALY WITH SEVERE COVID-19 Source text for Eikon: Further company coverage:
* FIBROGEN - UK HIGH COURT OF JUSTICE HAS HELD CERTAIN PATENTS RELATING TO METHODS OF USING HIF-PHIS TO BE INVALID
* FIBROGEN INC - AGREEMENT WITH SHANGHAI SYNTHEALL PHARMACEUTICAL CO LTD, STA PHARMACEUTICAL HONG KONG LIMITED FOR BULK MANUFACTURE/SUPPLY OF ROXADUSTAT
China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.